Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of RM-1929 in patients with recurrent Squamous Cell Head and Neck Cancer

Trial Profile

A phase I trial of RM-1929 in patients with recurrent Squamous Cell Head and Neck Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab sarotalocan (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Rakuten Medical
  • Most Recent Events

    • 08 Apr 2019 According to a Rakuten Medical media release, based upon the data of this and other phase I/II study, ASP-1929 received Sakigake designation under the Sakigake Designation System, which is a Fast Track designation from the Japanese Ministry of Health, Labour, and Welfare as a treatment for head and neck cancer patients."
    • 16 Jan 2018 Status changed from planning to recruiting according to an Aspyrian Therapeutics media release.
    • 21 Jul 2017 The MR states that the company is planning to start multiple phase I trials. However, the number of trials is not specified. I have created one CTP for now. Multiple profiles may have to be created later. I have assumed that trial will be conducted in patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top